Anaflex Gel 15g (Naproxen Sodium 10% Topical Gel) – ACI Limited

1. About Anaflex Gel 15g (Naproxen Sodium 10%)

Anaflex Gel 15g is a topical NSAID formulation containing Naproxen Sodium 10% w/w, manufactured by ACI Limited, Bangladesh. Applied directly to the skin over painful joints or muscles, it delivers therapeutic naproxen concentrations locally while maintaining very low systemic absorption — providing effective pain and inflammation relief with a significantly reduced risk of gastrointestinal, cardiovascular, and renal side effects compared to oral NSAIDs.

Anaflex Gel is particularly valuable for patients who cannot tolerate oral NSAIDs — including elderly patients, those with peptic ulcer disease, and patients with diabetes and chronic kidney disease who need pain relief for localised joint or musculoskeletal conditions. It is preferred in Bangladesh for knee osteoarthritis, sports injuries, and local soft tissue conditions.

2. Mechanism of Action

Naproxen sodium penetrates skin and underlying tissues after topical application, achieving local tissue concentrations sufficient to inhibit COX-1 and COX-2 enzymes at the site of inflammation. This reduces local prostaglandin synthesis (PGE2, PGI2), decreasing inflammation, vascular permeability, oedema, and pain sensitisation. Because the drug is delivered topically, systemic plasma concentrations remain far below those achieved with oral dosing — reducing systemic side effects while maintaining local efficacy.

3. Indications

• Osteoarthritis of the Knee: First-line topical NSAID — clinical guidelines (NICE, OARSI) recommend topical NSAIDs before oral NSAIDs in knee OA, especially in elderly and high-risk patients
• Acute Musculoskeletal Injuries: Sprains, strains, contusions, sports injuries — localised trauma pain and swelling
• Tendinitis and Bursitis: Shoulder, elbow (tennis/golfer's elbow), Achilles tendinitis
• Soft Tissue Rheumatism: Myofascial pain, localised muscle pain
• Post-Traumatic Pain
• Patients Who Cannot Take Oral NSAIDs: CKD, peptic ulcer, elderly, diabetics with renal impairment

4. Dosage and Administration

Adults: Apply a small amount (approximately 1–2cm of gel per 10cm² of affected area) to the painful area and gently massage in 3–4 times daily. Wash hands after application unless treating hands.

Duration: Up to 14 days for acute pain. Osteoarthritis treatment duration per physician guidance.

Do not apply to: Broken skin, open wounds, mucous membranes, eyes, or inflamed/infected skin. Do not apply under occlusive dressings unless advised by a physician.

Elderly and renal-impaired: Topical naproxen is preferred over oral NSAID — safe to use as systemic absorption is minimal. Nonetheless, avoid extensive area application.

5. Contraindications

• Known hypersensitivity to naproxen, other NSAIDs, or aspirin (including NSAID-sensitive asthma)
• Application to broken, abraded, infected, or eczematous skin
• Third trimester of pregnancy
• Children under 12 years (safety not established)

6. Warnings and Precautions

For external use only: Avoid contact with eyes, mouth, and mucous membranes. If contact occurs, flush with water.

Photosensitivity: Avoid sun exposure or UV lamps on treated areas during and for 2 weeks after use — topical NSAIDs may cause phototoxic reactions.

Skin reactions: Discontinue if rash, itching, or skin irritation develops at application site. Rare cases of contact dermatitis reported.

Pregnancy: Avoid in third trimester (systemic NSAID restriction applies topically too). Use with caution in first/second trimester — consult physician.

Diabetic patients — key advantage: Anaflex Gel is the preferred analgesic option for localised joint or muscle pain in diabetic patients with diabetic kidney disease (DKD). Unlike oral NSAIDs, topical naproxen does not meaningfully affect renal prostaglandins, GFR, blood pressure, or fluid balance — making it safe even in CKD stages 1–3. Also avoids oral NSAID interaction with sulphonylureas (hypoglycaemia risk) and ACE inhibitors/ARBs.

7. Side Effects

Local (common): Application-site reactions — mild burning, itching, erythema, or dry skin in 5–10% of users. Usually transient.

Local (uncommon): Contact dermatitis, vesicles, skin discolouration at application site.

Systemic: Very rare with correct topical use. Systemic absorption is only 1–6% of equivalent oral dose. Theoretical GI or cardiovascular effects possible only with extensive use over large areas.

8. Drug Interactions

Clinically significant systemic drug interactions are extremely unlikely with correct topical application. Theoretical concerns with anticoagulants (warfarin) or other NSAIDs only if extensive application results in significant systemic absorption. No interaction with oral diabetes medications at standard topical doses.

9. Pharmacokinetics

After topical application, naproxen sodium penetrates through the stratum corneum and achieves drug concentrations in underlying synovial tissue, tendons, and muscles that are 10–100× higher than plasma levels. Systemic bioavailability via skin ~1–6% of oral dose. Plasma Cmax is far below therapeutic oral levels. Hepatic metabolism (CYP2C9) and renal excretion — same as oral naproxen, but at negligible systemic concentrations.

10. Topical vs. Oral NSAIDs for Localised Pain

For localised joint or musculoskeletal pain, topical NSAIDs deliver comparable local efficacy to oral NSAIDs with a much improved systemic safety profile. A 2017 Cochrane Review of topical NSAIDs in knee OA found that topical diclofenac/naproxen gel achieved NNT similar to oral NSAIDs for pain relief, with significantly fewer GI adverse events. European League Against Rheumatism (EULAR) and OARSI guidelines recommend topical NSAIDs as first-line pharmacotherapy for knee OA — before oral NSAIDs, and as alternative to oral paracetamol in older patients with comorbidities.

11. Topical NSAID in Diabetic Arthritis Management

Diabetes is strongly associated with accelerated osteoarthritis — hyperglycaemia promotes cartilage glycation and degradation. Knee OA prevalence is approximately 2× higher in diabetic patients than in non-diabetic controls. Yet oral NSAIDs are hazardous in diabetic patients with CKD, hypertension, or those on ACE inhibitors/ARBs. Anaflex Gel fills this critical gap: it provides direct joint-level anti-inflammatory effect at the site of articular disease without systemic NSAID burden. It is the most recommended step in the analgesic ladder for diabetic patients with knee OA or localised musculoskeletal pain in international diabetes and rheumatology guidelines.

12. ACI Limited Anaflex Range

Anaflex Gel 15g is part of ACI Limited's comprehensive naproxen range, designed to address all clinical scenarios: Anaflex Gel 15g and 30g (topical — for localised pain with minimal systemic risk), Anaflex 250 mg and 500 mg tablets (oral standard dose), Anaflex SR 500 mg (sustained-release for twice-daily dosing), and Anaflex Max 375/500 mg (oral with esomeprazole for gastroprotection). The gel is especially recommended for elderly diabetic arthritis patients as first-choice local pain therapy.

13. Storage

• Store below 30°C, in a cool dry place. Do not freeze.
• Keep away from direct sunlight and heat. Keep tube tightly capped.
• Keep out of reach of children. Do not use after expiry date.

Frequently Asked Questions (FAQ)

Q1: What is Anaflex Gel used for?

Anaflex Gel 15g (Naproxen Sodium 10%) is used for localised pain and inflammation relief — knee osteoarthritis, sports injuries (sprains and strains), tendinitis, bursitis, and soft tissue musculoskeletal pain. It is applied directly to the skin over the painful area 3–4 times daily. It is particularly beneficial for patients who cannot safely take oral NSAIDs, including those with stomach problems, kidney disease, or diabetes.

Q2: Is Anaflex Gel safe for diabetic patients?

Yes — Anaflex Gel is one of the safest analgesic options for diabetic patients with localised joint pain. Unlike oral NSAIDs, topical naproxen has very low systemic absorption (1–6% of oral dose), so it does not meaningfully affect kidney function, blood pressure, or fluid balance. It does not interact with diabetes medications like metformin, insulin, or sulphonylureas. International guidelines recommend topical NSAIDs as first-line therapy for knee osteoarthritis in diabetic patients with chronic kidney disease.

Q3: How do I apply Anaflex Gel?

Squeeze a small amount (about 1–2 cm of gel per 10 cm² of skin area) onto clean, dry, intact skin over the painful joint or muscle. Gently massage in until absorbed. Apply 3–4 times daily. Wash hands after application (unless treating hands). Do not apply to broken, infected, or eczematous skin. Avoid eyes and mucous membranes. Avoid sunbathing or UV exposure on treated areas while using the gel.

Q4: What is the difference between Anaflex Gel 15g and 30g?

Both contain the same concentration of Naproxen Sodium 10% — the only difference is pack size. The 15g tube is suitable for acute injuries, short-term treatment, or a single localised site. The 30g tube provides better value for ongoing osteoarthritis management or multiple sites. For chronic knee OA requiring regular daily application, the 30g tube is more economical and reduces the need for frequent repurchase.